NEWS - 2010
Interface Biologics Receives ISO 13485:2003 Certification
Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative biomedical-polymer technology products, today announced that it received ISO 13485:2003 certification.
U of T is helping to create a culture of innovation
Dentistry professor Paul Santerre understands the world of start-up companies. Ten years ago, well before assuming his current role as director of the Institute of Biomaterials and Biomedical Engineering, Santerre discovered a way to control the adverse reactions of cells to medical implants. That idea sparked the establishment of Interface Biologics, a company that now employs 18 people, holds 10 patents and recently signed a deal with a multibillion-dollar health-care company specializing in dialysis systems.
Interface Biologics – Fresenius Medical Care Sign License Agreement
Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative biomedical-polymer technology products, is pleased to announce the signing of an evaluation and exclusive license option agreement with Fresenius Medical Care, the world's largest integrated provider of dialysis products and services.
Interface Biologics Inc’s Chief Scientific Officer Wins Julia Levy Award
Interface Biologics Inc. (IBI), a privately held developer of transformative bio-medical polymer technology that improves the safety and effectiveness of medical devices, is proud to announce that one of it's co-founders